Company Snapshot
Jupiter Neurosciences is a Biotech company, based in Jupiter, Florida, USA.
Recent changes
- Aug 20, 2026Aug 20, 2026Raised $775K SEC EDGAR Form D
- Jun 26, 2026Jun 26, 2026Jupiter Neurosciences Files an S-1 as It Pushes JOTROL Into Parkinson's Trials Pulse story
- Jun 26, 2026Jun 26, 2026Jupiter Neurosciences Files S-1 to Fund Its Neuroinflammation and Longevity Pipeline Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 20, 2026 | funding round | $775K | — | SEC EDGAR Form D |
Latest Pulse
- Jun 26, 2026Jupiter Neurosciences Files S-1 to Fund Its Neuroinflammation and Longevity PipelineClinical-stage biotech Jupiter Neurosciences (Nasdaq: JUNS) filed a Form S-1 with the SEC to register fresh capital as it advances its lead candidate JOTROL, a proprietary resveratrol platform targeting rare and neuroinflammatory CNS disorders and, increasingly, longevity. The filing adds another central-nervous-system name to a 2026 biotech pipeline that keeps widening alongside AI and chips.→
- Jun 26, 2026Jupiter Neurosciences Files an S-1 as It Pushes JOTROL Into Parkinson's TrialsClinical-stage biotech Jupiter Neurosciences (Nasdaq: JUNS) filed a Form S-1 with the SEC to register additional capital as it advances JOTROL, its enhanced resveratrol formulation, into a Phase 2a Parkinson's disease trial. The filing adds a CNS-focused name to a 2026 capital-markets pipeline that biotech is increasingly populating alongside AI and chips.→
- Jun 26, 2026Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics PipelineOllin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.→
Coverage Timeline
newest firstAll Coverage
IPOS-1 filed
Jupiter Neurosciences Files S-1 to Fund Its Neuroinflammation and Longevity Pipeline
Clinical-stage biotech Jupiter Neurosciences (Nasdaq: JUNS) filed a Form S-1 with the SEC to register fresh capital as it advances its lead candidate JOTROL, a proprietary resveratrol platform targeting rare and neuroinflammatory CNS disorders and, increasingly, longevity. The filing adds another central-nervous-system name to a 2026 biotech pipeline that keeps widening alongside AI and chips.
Jupiter Neurosciences Files an S-1 as It Pushes JOTROL Into Parkinson's Trials
IPOS-1 filed
Jupiter Neurosciences Files an S-1 as It Pushes JOTROL Into Parkinson's Trials
Clinical-stage biotech Jupiter Neurosciences (Nasdaq: JUNS) filed a Form S-1 with the SEC to register additional capital as it advances JOTROL, its enhanced resveratrol formulation, into a Phase 2a Parkinson's disease trial. The filing adds a CNS-focused name to a 2026 capital-markets pipeline that biotech is increasingly populating alongside AI and chips.
Related Companies
Jupiter Neurosciences FAQ
Is Jupiter Neurosciences publicly traded?
Yes. Jupiter Neurosciences trades under the ticker JUNS.
Sources & methodologyshow
Where these figures come from
- SEC EDGAR Form Dprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.